The latest data & strategies impacting the development of oncolytic viruses, from virus engineering and biomarker development through to navigating clinical trials
The programme brings together international pharmaceutical organisations, leading biotech companies and globally renowned academic institutions specialising in the development of oncolytic viruses
Full details on the Symposium including the presentations, topic areas and confirmed speakers will be released in the conference brochure in the coming weeks
Registration is now open for the Oncolytic Viruses Symposium. Please click the button below to register for this event.
Our LinkedIn group aims to foster discussion and collaboration between experts working in immunotherapy, autoimmunity and immuno-oncology
Engineering & Translational Strategies To Develop Oncolytic Virus Immunotherapy
Accelerating Oncolytic Virus Immunotherapy To The Clinic
The online Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry perspectives.
Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,200 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”
ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieux, which fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing.
As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedIn, Twitter and Facebook and subscribe to our mailing list.